From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Tom Winnifrith Bearcast: Maybe this time the odious bullshitter O'Leary is right

By Tom Winnifrith | Monday 18 May 2020


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


In today's podcast I look at the pronouncements from the odious leprechaun at Ryanair (RYA), Michael O'Leary. He may be right in what he says but that is no reason to buy airline shares. Then I cover Corero (CNS), Open Orphan (ORPH), where I am both vindicated after Friday's letter to AIM Regulation and also a seller of more shares today, Novacyt (NCYT), Collagen (COS), Falanx (FLX), and Bidstack (BIDS). Thanks to those who have donated to Rogue Bloggers for Woodlarks but most of you have not yet! Please do spare a few bob as the campsite needs our help urgently if it is to make it to 2021. Donate HERE

You must be a paid subscriber to listen to Bearcast
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 09:53:23